NCT06142708

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Embryolab Fertility Clinic · Academic / Other
• Sex: Female
• Age: 20 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to compare GnRH-agonist trigger with dual GnRH-agonist and HCG trigger in oocyte donors. The main questions it aims to answer are: * Maturation rate (Metaphase II/ Total number of COCs collected) * Fertilization rate * Embryo quality day 3 * Fragmentation rate embryo day 3 * Blastulation rate (Day5/6/7) * Quality of blastocyst (Gardner criteria) Participants will undergo controlled ovarian stimulation with a GnRH antagonist protocol Researchers will compare the effects of final maturation with GnRH-agonist trigger to a dual trigger (hCG and GnRH-a)

Detailed description

Final oocyte maturation is a critical step in the process of the Assisted Reproductive Technology (ART) treatment and has a certain impact on oocyte yield and oocyte competency. There are three different types of trigger: hCG, GnRH-agonist or dual trigger (hCG and GnRH-agonist combined), and the choice depends on the ovarian stimulation protocol, the ovarian response and on the clinical standard of the IVF clinic. As oocyte donors are at high risk for OHSS, a GnRH-agonist trigger (GnRH-a) is the most commonly used modality for triggering final maturation. However, a certain number of oocyte donors may have a suboptimal response to GnRH-a trigger only, with a yield of oocytes less than the 10th percentile, with a clear negative impact on oocyte efficiency and competency. This study aims to evaluate whether oocyte competence can be improved in oocyte donors with a previously suboptimal response to GnRH-a, by using a dual trigger in a subsequent ovarian stimulation cycle, in which hCG is added to the GnRH-agonist for final maturation

Conditions

• Ovarian Stimulation
• Human Chorionic Gonadotropin
• Oocyte Donors

Interventions

Type	Name	Description
DRUG	Dual trigger (human chorionic gonadotropin plus GnRH-agonist)	Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
DRUG	GnRH-agonist only trigger	GnRH-agonist only will be used for final maturation

Timeline

• Start date: 2023-11-01
• Primary completion: 2025-04-01
• Completion: 2026-02-01
• First posted: 2023-11-21
• Last updated: 2023-11-21

Locations

1 site across 1 country: Greece